高等学校化学学报 ›› 2011, Vol. 32 ›› Issue (9): 2187.

• 研究论文 • 上一篇    下一篇

1,2-二(2-胺基苯氧基)乙烷银配合物的合成与晶体结构

张奇龙2,张云黔1,朱必学1   

  1. 1. 贵州大学化学学院, 贵州省大环化学及超分子化学重点实验室, 贵阳 550025;
    2. 贵阳医学院化学教研室, 贵阳 550004
  • 收稿日期:2011-03-29 修回日期:2011-05-31 出版日期:2011-09-10 发布日期:2011-08-11
  • 通讯作者: 朱必学 E-mail:sci.bxzhu@gzu.edu.cn
  • 基金资助:

    国家自然科学基金(批准号: 21061003)和贵州省国际合作重点项目(批准号: 黔科合外G字[2009]700104)资助.

Synthesis and Crystal Structure of Four Silver Complexes with 1,2-Bis(2-amino-phenoxy)ethane

ZHANG Qi-Long2, ZHANG Yun-Qian1, ZHU Bi-Xue1*   

  1. 1. Key Laboratory of Macrocycle and Supramolecular Chemistry of Guizhou Province, College of Chemistry, Guizhou University, Guiyang 550025, China;
    2. Department of Chemistry, Guiyang Medical College, Guiyang 550004, China
  • Received:2011-03-29 Revised:2011-05-31 Online:2011-09-10 Published:2011-08-11
  • Contact: ZHU Bi-Xue E-mail:sci.bxzhu@gzu.edu.cn
  • Supported by:

    国家自然科学基金(批准号: 21061003)和贵州省国际合作重点项目(批准号: 黔科合外G字[2009]700104)资助.

摘要: 本文采用配体1, 2-二(邻氨基苯氧基)乙烷(L)分别与AgPF6, AgCF3SO3, AgNO3和AgSbF6 进行配位反应,依次得到了四个配合物1 [Ag2(L)2(PF6)]、2 [Ag2(L)2(CF3SO3)2]、3 [Ag(L)NO3]n 和4 [Ag(L)2SbF6]n,并通过FTIR、元素分析、以及X射线单晶衍射等对配合物的结构与组成进行了表征。单晶衍射结果表明,配合物1和2为双核银(I)配合物,3和4为银(I)的配位聚合物。配合物1具有穴状结构,2经Ag?Ag键桥连两个配体形成扭曲的非平面结构。聚合物3的结构为一维(1D)“之”字链,4具有三维(3D)多孔的结构框架。在四个配合物结构中,相应的抗衡阴离子均未参与Ag(I)进行配位作用。

关键词: 1, 2-二(2-胺基苯氧基)乙烷, Ag(I), 晶体结构

Abstract: The four complexes were synthesized from the reaction of 1,2-(2-aminophenoxy)ethane with AgX (X=PF6-, CF3SO3-, NO3- and AgSbF6-) respectively, and characterized by elemental analysis, FTIR and single crystal X-ray diffraction. The results of structural analysis indicate that both complexes 1 and 2 are dinuclear silver (I) complexes, while both complexes 3 and 4 are coordination polymers. The complex 1 is a cryptand, and 2 is a torsional structure formed by Ag-Ag bridging, 3 is 1D zigzag chain, and 4 is 3D porous frameworks. In the four complexes, the inorganic counter anion don’t coordinate with Ag(I).

Key words: 1,2-(2-Aminophenoxy)ethane, Silver(I), Crystal structure

TrendMD: